A B S T R A C T
Background. We evaluated the shedding of human immunodeficiency virus (HIV)-1 particles into continuous ambulatory peritoneal dialysis (CAPD) effluents of HIV-positive patients with end-stage renal disease (ESRD). Methods. A total of 58 HIV-positive patients with ESRD on highly active antiretroviral therapy (HAART) who had Tenckhoff catheters inserted between September 2012 and February 2015 were prospectively reviewed and followed for 18 months. Peritoneal dialysis (PD) effluent samples from functioning CAPD catheters and plasma samples were obtained at three points during regular clinic visits on days 45 6 37, 200 6 19 and 377 6 13 after catheter insertion. All specimens were stored at À20 C, and each batch was analysed by Roche quantitative HIV-1 polymerase chain reaction assay to detect HIV-1 particles. Clustered logistic regression was used to test for independent predictors of HIV-1 detection in CAPD effluents. Results. HIV-1 RNA above 20 copies/mL assay limit was detectable in 19% (first batch), 26 .3% (second batch) and 20% (third batch) of PD effluent specimens. HIV-1 RNA was detectable in PD fluid, without corresponding detection in the paired plasma in 3.4% (first batch), 5.3% (second batch) and 10% (third batch) of samples. Detection of HIV-1 in plasma sample (odds ratios 3.94; 95% confidence interval 1.14-13.55; P ¼ 0.030), body mass index, serum albumin and HAART regimen were found to be significantly associated with HIV-1 detection in PD effluents. Conclusions. HIV particles are shed in detectable amounts into CAPD effluents even in patients with suppressed plasma viral load, raising concerns of a localized sanctuary site and potential infectivity of HIV-positive CAPD patients on a full complement of HAART. [1, 2] . Although the incidence of new infections has been decreasing, the prevalence of people living with HIV continues to increase, mostly because of increased access to highly active antiretroviral therapy (HAART) and longer life expectancies [3] [4] [5] . As a result, non-communicable diseases such as chronic kidney disease (CKD) are expected to increase in this vulnerable population [6] . The general prevalence of CKD in SSA is estimated at approximately 13.9% and is expected to be even higher in the HIVpositive population [7] . While the incidence of HIV-associated end-stage renal disease (ESRD) has been stagnating in Western countries such as the USA [4, [8] [9] [10] , the rates are expected to increase significantly in SSA in proportion to the increased availability of HAART and the subsequent increase in life expectancy. Unfortunately, only a small proportion of those affected are expected to have access to renal replacement therapy [1, 7, 11] .
Continuous ambulatory peritoneal dialysis (CAPD) is a costeffective alternative to haemodialysis, particularly in low resource settings [12] [13] [14] . Its use in HIV-infected renal failure patients has raised concerns about risks to immediate household contacts and health care providers, since HIV particles have been identified in peritoneal dialysis (PD) effluents, suggesting potential infectivity in individuals not on a full complement of HAART [15] [16] [17] . Furthermore, HIV has been demonstrated to survive in both PD effluents and associated tubing for up to 3 days at room temperature, suggesting prolonged risk to immediate contacts if adequate disposal protocols are not followed [18] . However, with increased uptake of HAART and successful suppression of plasma HIV viral load to undetectable levels, the infectiveness of PD effluents is expected to attenuate. This study evaluated the shedding of HIV particles in CAPD effluents in patients with HIV infection-associated ESRD, who are currently on HAART.
M A T E R I A L S A N D M E T H O D S

Hospital sites
Patients were enrolled from King Edward VIII Hospital (KEH) and Inkosi Albert Luthuli Central Hospital (IALCH), Durban, South Africa.
Study population
This prospective cohort sub-study was extrapolated from a 70 HIV-positive patient cohort with newly inserted Tenckhoff catheters between September 2012 and February 2015 across the two hospitals. Consecutive incident CAPD patients aged 18-60 years were recruited. A total of 58 patients, with at least one PD fluid sample collected and stored successfully during the first year of follow-up, were included. The study protocol was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (BE 187/11), and all patients provided written informed consent prior to enrolment. All procedures were performed in accordance with the Helsinki Declaration. HIV status was confirmed by HIV-1 enzymelinked immunosorbent assay prior to enrolment, and treatment with HAART was initiated by the patients' local clinic as per South African ARV guidelines. Tenckhoff catheters were inserted by experienced surgeons; the majority of catheters were inserted during laparoscopy (n ¼ 30) at IALCH, while the remaining patients had percutaneous Tenckhoff catheter inserted by trained nephrologists at KEH (n ¼ 16) or at IALCH (n ¼ 12).
Enrolment and follow-up
Patients' demographic, clinical and biochemical data were recorded on enrolment. All patients were followed up at monthly intervals for 18 months at one central renal clinic in IALCH or until they died or their Tenckhoff catheter was removed. At each follow-up, vital signs, clinical parameters, anthropometric measurements, blood samples and PD fluid samples were obtained for all participants. Laboratory tests for full blood counts, serum levels of urea, creatinine, electrolytes, ferritin, albumin and C-reactive protein (CRP) were performed by the South African National Health Laboratory Service (NHLS), and results were periodically retrieved from the IALCH electronic results database. HIV-1 viral load at enrolment was analysed using the Abbott m2000 RealTime System by NHLS.
Sample collection and storage
Untimed PD effluent specimens (not timed to CAPD exchanges) were collected from functioning CAPD catheters, along with corresponding blood plasma specimens. Initially, these samples were obtained soon after successfully commencing cycles, and then during regular monthly clinic visits. For patients with complicated first use (due to malfunction, infection or mechanical complications), sampling was delayed until the first monthly clinic visit with a functioning Tenckhoff catheter, defined as a combined infusion and drainage time < 30min. A research nurse collected both blood samples (4 mL), using BD K 2 EDTA vacutainers and disposable needles, and PD effluent samples, using a sterile 10 mL syringe, from the Tenckhoff catheter into a sterile specimen bottle (discarding the first 10 mL of PD effluent aspirated). Both samples were transported on ice to the research laboratory where whole blood was centrifuged at 1500 RPM for 10 min, and plasma was separated in hooded benchtops. Both separated plasma and aliquoted PD effluent specimens were freeze-stored in Eppendorf tubes at À20 C throughout the study period.
Paired HIV-1 polymerase chain reaction analysis
The first paired specimens (PD effluent and plasma, 58 each) were withdrawn 45 6 37 days after Tenckhoff insertion and the second specimens (38 PD effluent and 38 plasma) were obtained from participants who had a patent catheter (taken at 200 6 19 days) for !180 days; samples were analysed at the same time in two batches when all participants had completed 6 months of dialysis. A third specimen batch (30 PD effluent and 30 plasma) was obtained at 377 6 13 days from participants who had a patent catheter for !365 days. Samples from the third batch were all analysed simultaneously when the participants had completed 1 year of dialysis. The timing of sampling in relation to insertion of the Tenckhoff catheter varied among participants due to missed scheduled clinic visits, temporary malfunctioning of Tenckhoff catheters or due to patients H I V -1 i n p e r i t o n e a l d i a l y s i s e f f l u e n t s
presenting on a non-CAPD clinic date when the research team was not available. All polymerase chain reaction (PCR) specimens were analysed by Lancet Laboratories, using Roche quantitative HIV-1 PCR assay (COBAS V R AmpliPrep/COBAS TaqMan V R analysis platform) to assess for the detectability of HIV-1 RNA.
Statistical analysis
Continuous variables were summarized as mean 6 standard deviation (SD), and medians and interquartile ranges (IQR) were used for variables that were highly skewed or contained prominent asymmetrical outliers. Categorical and ordinal variables were summarized using proportions and percentages. Proportions and categorical variables were compared using Pearson's chi-square test or Fisher's exact test, as appropriate. Wilcoxon signed-rank test was used to test for differences between paired PD and plasma viral loads. One-way analysis of variance was used to compare differences among the three batches for normally distributed variables. Kruskal-Wallis rank test was used to compare differences among the three batches for non-normally distributed variables. Clustered univariate logistic regression was used to assess the relationship between the detectability of HIV-1 particles in plasma samples and various measured variables against the detectability of HIV-1 particles in PD effluent samples. Clustered multivariable logistics regression analysis was used to identify independent predictors for detection of HIV-1 particles in PD effluent and plasma samples. All analyses were performed using Stata version 13.1 (StataCorp LP, College Station, TX, USA). The level of significance was set at P < 0.05.
R E S U L T S
Patient characteristics
We recruited 58 HIV-positive African CAPD patients, with a mean age of 35.8 6 9.0 years and including 56.9% women. In all, 53% (31/58) of patients were either newly diagnosed cases of HIV or had recently started HAART (<6 months prior to insertion of Tenckhoff catheter). A total of 48 (82.8%) subjects were on a standard regimen of lamivudine, efavirenz and abacavir as per South African ARV treatment guidelines for patients with renal impairment. The other 10 subjects were on either modified first-line or second-line treatment regimens, depending on individual circumstances. Around 59% (34/58) of the participants had a suppressed viral load at the time of enrolment, as determined by the hospital laboratory assay limit of 150 copies/ mL. The median baseline viral load for patients with detectable viral loads was 4564 copies/mL (IQR 980-88 294), but this value dropped below the detectable limit (IQR <150-3379) if patients with undetectable HIV-1 viral loads were included in the analysis. Additional baseline characteristics of the study population are outlined in Table 1 .
HIV-1 PCR analysis
Approximately, 53% (31/58) of samples from the first plasma specimen batch had detectable HIV-1 particles above the 20 copies/mL assay limit, whereas only 19% (11/58) of corresponding PD effluent specimens had detectable HIV-1 particles. Around 61% (19/31) of detectable first plasma specimens and 72.7% (8/11) of detectable PD effluent specimens were from patients who had first initiated ARV therapy within 6 months of Tenckhoff catheter insertion. Roughly 26% (10/38) of the second PD effluent specimens and 20% (6/30) third PD effluent specimens had detectable HIV-1 particles (Supplementary data, Table S1 ).
HIV-1 viral load was detected in both paired plasma and PD fluid samples in 15.5% (9/58) of the first specimen batch, 21% (8/38) of the second specimen batch and 10% (3/30) of the third specimen batch. HIV-1 was detected in PD fluid, without being detected in the paired plasma specimen in 3.4% (2/58) of first batch specimens, 5.3% (2/38) of second batch specimens and 10% (3/30) of third batch specimens (P ¼ 0.417) ( Table 2 ). Around 3% (2/58) of subjects had at least one PD fluid specimen in which HIV-1 was detectable, while it remained undetectable in all three corresponding plasma specimens.
HIV-1 viral load logs of PD effluents were significantly lower than those of plasma for specimen batches 1 and 2 (both P < 0.001) and borderline significant for batch 3 (P ¼ 0.058). However, there were no significant differences between individual batched viral load logs in PD effluent or plasma samples ( Figure 1 ).
Clustered univariate and multivariable logistic regression analysis
On univariate logistic analysis, detectable plasma HIV-1 viral load was a significant factor for detection of HIV-1 particles in PD effluents in the combined batch specimen pool [odds ratios (OR) 4.21; 95% confidence interval (CI) 1.61-11.05; P ¼ 0.003]. Serum albumin level (OR 0.91; CI 0.85-0.98; P ¼ 0.014), body mass index (BMI) (OR 0.90; CI 0.82-0.99; P ¼ 0.025) and HAART drug regimen type were significantly associated with detection of HIV-1 in PD effluents (Table 3) .
A multivariable logistics regression model identified plasma HIV-1 viral load > 20 copies/mL (OR 3.44; 95% CI 1.09-10.80; P ¼ 0.035), serum albumin (OR 0.86; 95% CI 0.76-0.98; P ¼ 0.020), BMI (OR 0.81; 95% CI 0.68-0.98; P ¼ 0.031), haemoglobin (OR 1.43; 95% CI 1.12-1.82; P ¼ 0.004), nevirapine and aluvia (Lopinavir/Ritonavir)-containing HAART regimens and HAART duration >1 year at the time of study enrolment to be independent predictors for the detectability of HIV-1 viral particles in PD fluid. In a separate multivariable logistics regression analysis, we identified age (OR 0.92; CI 0.85-0.99; P ¼ 0.019), HAART duration >1 year (OR 0.22; CI 0.05-0.97; P ¼ 0.045), lamivudine-efavirenz-stavudine containing HAART drug regimen (OR 0.05; CI 0.00-0.66; P ¼ 0.024) and having high school or higher education as significant factors associated with decreased odds of detecting of HIV-1 in the plasma (Table 3) .
Peritoneal dialysis effluent white blood cell count (4/27) were from patients with associated PD WCC !100 cells/mL. PD WCC was not associated with HIV-1 detection on univariate logistic regression (OR 1.00; CI 1.00-1.00; P ¼ 0.501) and was not a predictor of HIV-1 detection in PD effluent on multivariable logistic regression (OR 1.00; CI 1.00-1.01; P ¼ 0.454). Having a peritonitis experience (one or more peritonitis episodes) during follow-up was associated with non-significant ORs for detection of HIV-1 viral load on PD effluents on univariate and multivariate logistic regression analysis (OR 1.75; CI 0.68-4.52; P ¼ 0.248 and OR 0.44; CI 0.12-1.61; P ¼ 0.216, respectively).
D I S C U S S I O N
This prospective cohort study evaluated the shedding of HIV-1 particles in CAPD effluents of HAART-treated HIV-infected patients with ESRD. To our knowledge, this is the first study to prospectively evaluate HIV-1 viral loads in a relatively large population of HIV patients being treated with HAART while on CAPD. Our study also demonstrated a significant increase in the OR for HIV-1 particle detection in PD effluents if plasma HIV-1 viral load was not suppressed below detectable levels. This highlights the importance of optimizing HIV treatment, as uncontrolled HIV infection can increase the risk for shedding of HIV-1 particles into CAPD effluents, as observed in previous pre-HAART era studies [15] [16] [17] .
A substantial proportion of our patients failed to have suppressed plasma viral load below detectable limits at 6 months (50%) and 1 year (33%) follow-up. The most likely cause of this is poor treatment adherence, although we cannot exclude the contribution of low antiviral effectiveness, pharmacokinetic properties and the development of drug-resistant strains to this observation, as these were not specifically investigated [19] . Multivariable logistic regression revealed that HAART duration of >1 year at the time of enrolment, having high school or higher education, age and a lamivudine-efavirenz-stavudinecontaining HAART drug regimen were protective factors against HIV-1 detectability in plasma. Although some of these associations were not confirmed on univariate analysis, they demonstrate the importance of optimal treatment compliance and stable sustained HAART therapy on achieving virologic suppression. It has been previously demonstrated that younger age is associated with poor compliance [20] . Our study showed that age is a protective factor against HIV-1 detectability in plasma and that older age may be associated with better medication compliance and, as a result, reduced HIV-1 detectability. Plasma viral suppression has been suggested as an alternative measure of drug adherence comparable to patient self-reported estimates [21] . In their study of a rural South African adult HIV-treatment cohort, Mutevedzi et al. [22] demonstrated an overall virologic response rate of 86.3%, with a higher proportion of older adults showing better suppression than younger adults. This suppression rate was much higher than the 66.7% demonstrated for the ESRD CAPD population in our study, Median, copies/mL (IQR) 4564 (87 314) <150 copies/mL, number (%) of subjects 34 (58.6%) 150-1000 copies/mL, number (%) of subjects 6 (10.3) >1000 copies/mL, number (%) of subjects 18 (31.0) HAART history at enrolment despite the fact that both sample populations were sourced from the same province and share a similar socioeconomic background. We hypothesize that psychosocial factors aggravated by the combined diagnosis of end-stage renal failure and HIV may have contributed to suboptimum compliance and the observed lower suppression rates in this special population group.
A notable proportion of patients had detectable HIV-1 particles in the PD effluents in the absence of detectable levels in corresponding plasma samples (3.4% at 45 days, 5.3% at 200 days and 10.0% at 377 days). This finding was consistent with that reported by Calcagno et al. [23] , who demonstrated the presence of HIV-1-RNA in the peritoneal fluid of an HIVpositive end-stage liver disease patient with suppressed plasma viral load. The authors attributed this finding to the reduced penetration of some ARV drugs into the peritoneal cavity and hypothesized that active replication of HIV-1 in gut-associated lymphoid tissue or in abdominal lymph nodes may have contributed to this finding [23, 24] . HIV-1 detection in PD fluid samples of patients with undetectable plasma viral load raises concerns of a localized sanctuary site. However, whether this detection indicates ongoing active localized viral replication requires further investigation.
Serum albumin level and BMI were identified as protective factors against HIV-1 detection in PD effluents in univariate analysis and as independent predictors in our multivariate logistic regression model. These findings suggest that malnutrition may be a factor in the shedding of HIV-1 into PD effluents. Reduced plasma levels of some ARV drugs have been reportedly associated with diarrhoea/wasting syndrome, and the latter further associated with low BMI and CD4 count [25] . Malnutrition and inflammation may induce structural and functional changes in bowel mucosa, resulting in impaired absorption of certain ARV drugs. However, small drug dosages taken by those who are underweight, particularly of efavirenz, could also have contributed to observed associations for BMI and HIV-1 detection in PD effluents. The type of HAART drug regimen was also identified as an important factor in HIV-1 detection in PD effluents, with nevirapine and aluvia (lopinavir/ritonavir) containing regimens being associated with increased odds. The majority of our patients (82.8%) were on treatment regimens containing lamivudine, efavirenz and abacavir, as per South African treatment guidelines, with abacavir serving as a substitute for tenofovir in renal failure patients [26] . Lamivudine was used by all of our study participants and has been reported to have good penetration into many body fluid compartments including the peritoneal cavity [23, 27] . Interestingly, the maximum serum concentration or the area under the serum concentration-time curve of CAPD patients is not affected by reduced renal dosing [28, 29] . A case report by Izzedine et al. [30] demonstrated that ritonavir (a large tightly protein bound molecule) has poor transport across the peritoneal membrane and a negligible extraction ratio (1%). Nevirapine is a smaller protein bound molecule associated with approximately 50% lower peritoneal concentrations compared with plasma [30, 31] . However, there is a general paucity of data on peritoneal penetration or stability of most ARV drugs in CAPD patients under conditions of continual peritoneal lavage by dialysis fluid. The effect of different ARV drugs and combinations in suppressing viral replication in localized peritoneal sites requires further investigation.
This study has several limitations. First, PD effluent sampling was not timed to CAPD bag exchanges. Untimed samples were collected as patients arrived to the clinic and were seen by the research team. Since participants were part of a larger renal clinic community and some travelled from as far as 400 km, coordinating timed sampling was logistically difficult. However, this method did not significantly alter the associations observed for HIV-1 viral load detectability in PD effluent, as untimed sampling would have been expected to decrease the sensitivity of HIV-1 detection with the consequence of underestimating the measured effects rather than enhancing them. Secondly, the management of HAART regimens was left to the discretion and professional opinion of the local ARV clinics, which were guided by clinical treatment guidelines. Therefore, there was no strict supervision over HAART management decisions or individual exploration of underlying reasons for failure to supress. Thirdly, this was a sub-study with the overall sample size calculated according to an anticipated peritonitis-based effect size contrasted against an HIV-negative cohort, and the HAART regimens were not factored in the design or selection of patients. The small sample of patients with regimens different from the clinical standard limits the generalizability of some of these findings. Further studies are needed to evaluate the pharmacokinetics and effectiveness of commonly utilized HAART drugs in CAPD, as well as to investigate the possible causes of failure to suppress. This study demonstrated that HIV particles are shed in detectable amounts into the CAPD effluents of HAART-treated ESRD patients with unsuppressed, and in some instances suppressed, viral loads. This study highlights the importance of sociodemographic factors, nutritional indicators and sustained effective HAART regimens in determining successful suppression of HIV-1 in plasma and PD effluents.
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